Microspheres containing neutralizing antibodies to tumor necrosis factor-α and interleukin-1β protect rats from Staphylococcus aureus-induced peritonitis

Journal of Interferon and Cytokine Research

Volumn 20, Issue 10, 2000, Pages 907-913

  D'Souza, M ^a   Oettinger, C W ^a   Milton, G V ^b  

^a MERCER UNIVERSITY   (United States)

^b Dialysis Clinic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; INTERLEUKIN 1BETA; MICROSPHERE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BACTERIAL PERITONITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GRAM NEGATIVE SEPSIS; MICROENCAPSULATION; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

ANIMALS; ANTIBODIES; INTERLEUKIN-1; MICROSPHERES; PERITONITIS; RATS; RATS, INBRED F344; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033771299     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900050163280     Document Type: Article

References (49)

1. Veterans administration study group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systematic sepsis
2. Infections due to Staphylococcus aureus
3. Staphylococcus aureus: The persistent pathogen
4. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
5. Activation of coagulation after administration of tumor necrosis factor to normal subjects
6. Shock and tissue injury induced by recombinant human cachetin
7. Acute in vivo effects of human recombinant tumor necrosis factor
8. Blood cytokine and complement levels in patients with sepsis
9. Correlation of plasma cytokine elevations with mortality rate in children with sepsis
10. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease
11. Prognostic value of tumor necrosis factor/cachetin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock
12. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
13. The complex pattern of cytokines in serum from patients with meningococcal septic Shock. Association between interleukin-6 interleukin-1, and fatal outcome
14. Serum cachetin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality
15. Plasma tumor necrosis factor and mortality in critically ill septic patients
16. Capsular polysaccharide types 5 and 8 of Staphylococcus aureus bind specifically to human epithelial (KB) cells, endothelial cells and monocytes and induce release of cytokines
17. Murine macrophage activation by staphylococcal exotoxins
18. Early activation events induced by the staphylococcal superantigen toxic shock syndrome toxin-1 in human peripheral blood monocytes
19. Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia
20. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock but fails to alter host responses to sublethal endotoxemia
21. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis
22. Lethal Staphylococcus aureus-induced shock in primates: Prevention of death by anti-TNF antibody
23. Anti-inflammatory therapies to treat sepsis and septic shock: A reassement
24. Prolongation of murine cardiac allograft survival by microspheres containing TNF alpha and IL-1 beta neutralizing antibodies
25. Evaluation of microspheres containing cytokine neutralizing antibodies in endotoxemia
26. Prevention of lethality in suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493
27. Macrophage depletion by albumin microencapsulated clodronate: Attenuation of cytokine release in macrophage-dependent glomerulonephritis
28. Controlled release of cyclosporin from microspheres
29. Site-specific microencapsulated drug targeting strategies - Liver and gastrointestinal tract targeting
30. Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram-negative peritonitis
31. Enzyme-linked immunosorbent assay for detection of human tumor necrosis factor alpha
32. Enzyme-linked immunosorbent assay for detection of human interleukin-1beta
33. Role of cytokines in sepsis
34. Differential regulation by staphlococcal enterotoxins A and B in murine macrophages
35. Interleukin-10 protects mice against staphlococcal enterotoxin B-induced lethal shock
36. Inhibition of toxic shock syndrome toxin-1 induced cytokine production and T cell activation by interleukin-10, interleukin-4, and dexamethasone
37. Synergistic induction of interleukin-1 by endotoxin and toxic shock syndrome toxin-1 using rat macrophages
38. Staphlococcus induces complement activation, tumor necrosis factor and interleukin-1, a shock like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli
39. Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphlococcus aureus challenge in a canine model of human septic shock
40. Staphlococcus aureus-induced shock: A pathlophysiologic study
41. Production of tumor necrosis factor by human monocytes in response to toxic-shock syndrome toxin-1
42. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production
43. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans
44. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture of endotoxemia
45. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor
46. Study of septic shock in non-human primate: Relationship of pathophysiological response to therapy with anti-TNF antibody
47. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model
48. Intracellular targeting and release of IL-1 neutralizing antibodies from albumin microspheres
49. Distribution profile of albumin microspheres containing cytokine neutralizing antibodies in normal and infected rats